These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 18207105)

  • 1. Minocycline for patients with ALS.
    Carrì MT
    Lancet Neurol; 2008 Feb; 7(2):118-9; author reply 120-1. PubMed ID: 18207105
    [No Abstract]   [Full Text] [Related]  

  • 2. Minocycline for patients with ALS.
    Leigh PN; Meininger V; Bensimon G; Cudkowicz M; Robberecht W
    Lancet Neurol; 2008 Feb; 7(2):119-20; author reply 120-1. PubMed ID: 18207106
    [No Abstract]   [Full Text] [Related]  

  • 3. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS.
    Zhang W; Narayanan M; Friedlander RM
    Ann Neurol; 2003 Feb; 53(2):267-70. PubMed ID: 12557297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis.
    Kriz J; Nguyen MD; Julien JP
    Neurobiol Dis; 2002 Aug; 10(3):268-78. PubMed ID: 12270689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions with GluR1 AMPA receptors could influence the therapeutic usefulness of minocycline in ALS.
    Manev H; Manev R
    Amyotroph Lateral Scler; 2009; 10(5-6):416-7. PubMed ID: 19922133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient three-drug cocktail for disease induced by mutant superoxide dismutase.
    Kriz J; Gowing G; Julien JP
    Ann Neurol; 2003 Apr; 53(4):429-36. PubMed ID: 12666110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Minocycline for the treatment of amyotrophic lateral sclerosis: neuroprotector or neurotoxin? Reflections on another failure of translational medicine].
    Gámez J
    Neurologia; 2008 Oct; 23(8):484-93. PubMed ID: 18802797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with minocycline after disease onset alters astrocyte reactivity and increases microgliosis in SOD1 mutant mice.
    Keller AF; Gravel M; Kriz J
    Exp Neurol; 2011 Mar; 228(1):69-79. PubMed ID: 21168408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of preclinical trial timing - a potential reason for the disconnect between mouse studies and human clinical trials in ALS.
    Kong Q; Carothers S; Chang Y; Glenn Lin CL
    CNS Neurosci Ther; 2012 Sep; 18(9):791-3. PubMed ID: 22712693
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of apoptosis in neuromuscular diseases and prospects for anti-apoptosis therapy.
    Miller JB; Girgenrath M
    Trends Mol Med; 2006 Jun; 12(6):279-86. PubMed ID: 16650805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lost in translation: treatment trials in the SOD1 mouse and in human ALS.
    Benatar M
    Neurobiol Dis; 2007 Apr; 26(1):1-13. PubMed ID: 17300945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical research. ALS trial raises questions about promising drug.
    Couzin J
    Science; 2007 Nov; 318(5854):1227. PubMed ID: 18033854
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.
    Gordon PH; Moore DH; Miller RG; Florence JM; Verheijde JL; Doorish C; Hilton JF; Spitalny GM; MacArthur RB; Mitsumoto H; Neville HE; Boylan K; Mozaffar T; Belsh JM; Ravits J; Bedlack RS; Graves MC; McCluskey LF; Barohn RJ; Tandan R;
    Lancet Neurol; 2007 Dec; 6(12):1045-53. PubMed ID: 17980667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroscience: Standard model.
    Schnabel J
    Nature; 2008 Aug; 454(7205):682-5. PubMed ID: 18685674
    [No Abstract]   [Full Text] [Related]  

  • 15. Minocycline-induced skin and dental pigmentations.
    Mozaffar T; Gordon PH
    Neurology; 2006 Dec; 67(12):2185. PubMed ID: 17190941
    [No Abstract]   [Full Text] [Related]  

  • 16. Minocycline delays disease onset and mortality in a transgenic model of ALS.
    Van Den Bosch L; Tilkin P; Lemmens G; Robberecht W
    Neuroreport; 2002 Jun; 13(8):1067-70. PubMed ID: 12060810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis.
    Gordon PH; Moore DH; Gelinas DF; Qualls C; Meister ME; Werner J; Mendoza M; Mass J; Kushner G; Miller RG
    Neurology; 2004 May; 62(10):1845-7. PubMed ID: 15159491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Edaravone in ALS.
    Takahashi R
    Exp Neurol; 2009 Jun; 217(2):235-6. PubMed ID: 19285071
    [No Abstract]   [Full Text] [Related]  

  • 19. Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model.
    Waibel S; Reuter A; Malessa S; Blaugrund E; Ludolph AC
    J Neurol; 2004 Sep; 251(9):1080-4. PubMed ID: 15372249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlates of quality of life in ALS: Lessons from the minocycline study.
    Lou JS; Moore D; Gordon PH; Miller R
    Amyotroph Lateral Scler; 2010; 11(1-2):116-21. PubMed ID: 19551536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.